Abstract
Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented
Keywords: Active targeting, cancer therapy, nanocarriers, passive targeting, stealth, inflammation, nucleic acid, Tumour vasculature, epithelium, endothelium
Current Drug Discovery Technologies
Title: Passive and Active Tumour Targeting with Nanocarriers
Volume: 8 Issue: 3
Author(s): Samuli Hirsjarvi, Catherine Passirani and Jean-Pierre Benoit
Affiliation:
Keywords: Active targeting, cancer therapy, nanocarriers, passive targeting, stealth, inflammation, nucleic acid, Tumour vasculature, epithelium, endothelium
Abstract: Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented
Export Options
About this article
Cite this article as:
Hirsjarvi Samuli, Passirani Catherine and Benoit Jean-Pierre, Passive and Active Tumour Targeting with Nanocarriers, Current Drug Discovery Technologies 2011; 8 (3) . https://dx.doi.org/10.2174/157016311796798991
DOI https://dx.doi.org/10.2174/157016311796798991 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Biological Effects and Toxicity of Cetyltrimethylammonium Bromide Stabilized Silver Nanoparticles and Cetyltrimethylammonium Bromide Alone Following Intravenous Injection in Mice
Current Nanomedicine Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Angiogenesis and Hypoxia in Glioblastoma: A Focus on Cancer Stem Cells
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry Dual Receptor-Specific Peptides Modified Liposomes as VEGF siRNA Vector for Tumor-Targeting Therapy
Current Gene Therapy Cytotoxic Effects of Blue Scorpion Venom (<i>Rhopalurus junceus</i>) in a Glioblastoma Cell Line Model
Current Pharmaceutical Biotechnology VEGF and HIF in Renal Cell Carcinogenesis
Recent Patents on Biomarkers Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Current Signal Transduction Therapy Astrocytic Target Mechanisms in Epilepsy
Current Medicinal Chemistry Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms Regulating the Mitochondrial Targeting of Microsomal Cytochrome P450 EnzymesMolecular Mechanisms Regulating the Mitochondrial Targeting of Microsomal Cytochrome P450 Enzymes
Current Drug Metabolism Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry Neovascular Age-related Macular Degeneration: Past, Present, and Future
Current Angiogenesis (Discontinued) Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry